Get the Stockscreener App
31.37
2.40%
-0.77
After Hours:
31.37
Avidity Biosciences Inc stock is traded at $31.37, with a volume of 963.43K.
It is down -2.40% in the last 24 hours and up +4.99% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$32.14
Open:
$31.22
24h Volume:
963.43K
Relative Volume:
0.62
Market Cap:
$4.37B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-10.85
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-13.44%
1M Performance:
+4.99%
6M Performance:
-3.45%
1Y Performance:
-21.50%
1-Day Range:
$30.93
$31.73
1-Week Range:
$30.93
$38.00
52-Week Range:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
31.37 | 4.37B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com India
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity's Muscular Dystrophy Drug Del-brax Gets FDA Accelerated Approval Path: Key Data Coming - Stock Titan
Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation - MSN
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Avidity Biosciences holds annual stockholders meeting - Investing.com
Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance
JP Morgan Raises Price Target for Avidity Biosciences (RNA) to $59 | RNA Stock News - GuruFocus
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts - Nasdaq
Avidity Biosciences (RNA) Sees Price Target Increase Amid Promis - GuruFocus
Avidity Biosciences (RNA) Gains Boost with New Price Target and Accelerated Approval Path | RNA Stock News - GuruFocus
Barclays Raises Target Price for Avidity Biosciences (RNA) | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Price Target Raised Amid Positive Deve - GuruFocus
RNA: Avidity Biosciences Maintains Buy Rating with Price Target Increase | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Seeks Accelerated Approval for Key Drug | RNA Stock News - GuruFocus
Avidity Biosciences stock falls following positive trial data By Investing.com - Investing.com Canada
BofA lifts Avidity Biosciences stock target to $54 By Investing.com - Investing.com Canada
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Benzinga
Avidity Biosciences (RNA) Receives Enhanced Price Target Followi - GuruFocus
Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - marketscreener.com
Avidity Biosciences (RNA) Receives Enhanced Price Target Following Trial Results | RNA Stock News - GuruFocus
Avidity Biosciences Shares Face Turbulence Amid Mixed Signals - TipRanks
Avidity Biosciences (RNA) Reports Promising Results from FSHD Treatment Study | RNA Stock News - GuruFocus
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants - BioSpace
Avidity Biosciences (RNA) Advances Del-brax Approval Pathway for FSHD Treatment | RNA Stock News - GuruFocus
Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients - marketscreener.com
Avidity reports promising FSHD therapy trial results - Investing.com
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - WV News
Stocks Flashing Renewed Technical Strength: Avidity Biosciences - Investor's Business Daily
(RNA) Investment Analysis - news.stocktradersdaily.com
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider
Avidity Biosciences Target of Unusually Large Options Trading (NASDAQ:RNA) - Defense World
Stifel Financial Corp Cuts Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for RNA - Defense World
FY2025 EPS Estimates for RNA Lowered by Cantor Fitzgerald - Defense World
When (RNA) Moves Investors should Listen - news.stocktradersdaily.com
Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Avidity Biosciences Reports Q1 2025 Earnings - TipRanks
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $68.00 by Analysts at HC Wainwright - Defense World
Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald
Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus
Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):